{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:58:09Z","timestamp":1775728689202,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"DOI":"10.7759\/cureus.106698","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:05:18Z","timestamp":1775725518000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Proton Pump Inhibitor Therapy on Bone Mineral Density: An Updated Systematic Review"],"prefix":"10.7759","author":[{"given":"Chalini","family":"Sundar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshan","family":"Devang Divakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Saravana","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annapoorani","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091569","article-title":"Proton pump inhibitors (PPIs)-an evidence-based review of indications, efficacy, harms, and deprescribing","volume":"61","author":"Andrawes M","year":"2025","unstructured":"Andrawes M, Andrawes W, Das A, Siau K. Proton pump inhibitors (PPIs)-an evidence-based review of indications, efficacy, harms, and deprescribing. Medicina (Kaunas). 2025, 61:1569. 10.3390\/medicina61091569","journal-title":"Medicina (Kaunas)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810733","article-title":"Proton pump inhibitors and bone health: an update narrative review","volume":"23","author":"Lespessailles E","year":"2022","unstructured":"Lespessailles E, Toumi H. Proton pump inhibitors and bone health: an update narrative review. Int J Mol Sci. 2022, 23:10733. 10.3390\/ijms231810733","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand DS","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017, 11:27-37. 10.5009\/gnl15502","journal-title":"Gut Liver"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.725359","article-title":"Prolonged use of proton pump inhibitors, but not histamine-2 receptor antagonists, is associated with lower bone mineral density in males aged over 70","volume":"8","author":"Gao S","year":"2021","unstructured":"Gao S, Song W, Lin T, Chen W, He W, Wei Q, Li Z. Prolonged use of proton pump inhibitors, but not histamine-2 receptor antagonists, is associated with lower bone mineral density in males aged over 70. Front Med (Lausanne). 2021, 8:725359. 10.3389\/fmed.2021.725359","journal-title":"Front Med (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.166","article-title":"We are using too many PPIs, and we need to stop: a European perspective","volume":"111","author":"Lanas A","year":"2016","unstructured":"Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol. 2016, 111:1085-6. 10.1038\/ajg.2016.166","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.10.007","article-title":"The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal","volume":"37","author":"Savarino V","year":"2017","unstructured":"Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2017, 37:19-24. 10.1016\/j.ejim.2016.10.007","journal-title":"Eur J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297921100035","article-title":"Effect of omeprazole on osteoblasts and osteoclasts in vivo and in the in vitro model using fish scales","volume":"86","author":"Zanaty MI","year":"2021","unstructured":"Zanaty MI, Abdel-Moneim A, Kitani Y, Sekiguchi T, Suzuki N. Effect of omeprazole on osteoblasts and osteoclasts in vivo and in the in vitro model using fish scales. Biochemistry (Mosc). 2021, 86:1192-200. 10.1134\/S0006297921100035","journal-title":"Biochemistry (Mosc)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review","volume":"123","author":"Haastrup PF","year":"2018","unstructured":"Haastrup PF, Thompson W, S\u00f8ndergaard J, Jarb\u00f8l DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018, 123:114-21. 10.1111\/bcpt.13023","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82102","article-title":"Effects of long-term proton pump inhibitor use on serum electrolytes and vitamin levels: a quasi-experimental study in Pakistan","volume":"17","author":"Khan A","year":"2025","unstructured":"Khan A, Hussain M, Ahmed A, Nazir N, Malik MK, Saeed N. Effects of long-term proton pump inhibitor use on serum electrolytes and vitamin levels: a quasi-experimental study in Pakistan. Cureus. 2025, 17:e82102. 10.7759\/cureus.82102","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1577820","article-title":"Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies","volume":"18","author":"Wang CH","year":"2019","unstructured":"Wang CH, Li CH, Hsieh R, et al.. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2019, 18:163-72. 10.1080\/14740338.2019.1577820","journal-title":"Expert Opin Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.12.058","article-title":"Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis","volume":"218","author":"Liu J","year":"2019","unstructured":"Liu J, Li X, Fan L, Yang J, Wang J, Sun J, Wang Z. Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis. Life Sci. 2019, 218:213-23. 10.1016\/j.lfs.2018.12.058","journal-title":"Life Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gerinurse.2025.103596","article-title":"Proton pump inhibitors and risk of fracture in older adults: a systematic review and meta-analysis","volume":"66","author":"Robert V","year":"2025","unstructured":"Robert V, Papailhau C, Lesclide E, Ben Romdhane Z, Vincentelli MB, Franqui C, Grino M. Proton pump inhibitors and risk of fracture in older adults: a systematic review and meta-analysis. Geriatr Nurs. 2025, 66:103596. 10.1016\/j.gerinurse.2025.103596","journal-title":"Geriatr Nurs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong BK","year":"2019","unstructured":"Thong BK, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019, 16:1571. 10.3390\/ijerph16091571","journal-title":"Int J Environ Res Public Health"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2023-0198","article-title":"Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density","volume":"10","author":"Smaoui H","year":"2024","unstructured":"Smaoui H, Chtourou L, Jallouli D, et al.. Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density. Future Sci OA. 2024, 10:FSO977. 10.2144\/fsoa-2023-0198","journal-title":"Future Sci OA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13661","article-title":"Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults","volume":"63","author":"Hinson AM","year":"2015","unstructured":"Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC Jr, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015, 63:2070-3. 10.1111\/jgs.13661","journal-title":"J Am Geriatr Soc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/a-2009-9629","article-title":"Long-term proton pump inhibitor therapy and its effect on endocrine hormones in selected patient population","volume":"55","author":"Ashfaq M","year":"2023","unstructured":"Ashfaq M, Khan Q, Haroon MZ, Abid SM, Sharif MJ, Alkahraman YM. Long-term proton pump inhibitor therapy and its effect on endocrine hormones in selected patient population. Horm Metab Res. 2023, 55:205-11. 10.1055\/a-2009-9629","journal-title":"Horm Metab Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5009\/gnl14135","article-title":"A proton pump inhibitor\u2019s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study","volume":"9","author":"Jo Y","year":"2015","unstructured":"Jo Y, Park E, Ahn SB, et al.. A proton pump inhibitor\u2019s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut Liver. 2015, 9:607-14. 10.5009\/gnl14135","journal-title":"Gut Liver"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101741","article-title":"Osseous implications of proton pump inhibitor therapy: An umbrella review","volume":"20","author":"Alanazi AS","year":"2024","unstructured":"Alanazi AS, Almutairi H, Gupta JK, et al.. Osseous implications of proton pump inhibitor therapy: An umbrella review. Bone Rep. 2024, 20:101741. 10.1016\/j.bonr.2024.101741","journal-title":"Bone Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100732","article-title":"Effect of proton pump inhibitors on bone mineral density: A systematic review and meta-analysis of observational studies","volume":"13","author":"Aleraij S","year":"2020","unstructured":"Aleraij S, Alhowti S, Ferwana M, Abdulmajeed I. Effect of proton pump inhibitors on bone mineral density: A systematic review and meta-analysis of observational studies. Bone Rep. 2020, 13:100732. 10.1016\/j.bonr.2020.100732","journal-title":"Bone Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06817-4","article-title":"Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging","volume":"34","author":"Shevroja E","year":"2023","unstructured":"Shevroja E, Reginster JY, Lamy O, et al.. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int. 2023, 34:1501-29. 10.1007\/s00198-023-06817-4","journal-title":"Osteoporos Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2018.06.008","article-title":"Lower Trabecular Bone Score is Associated With the Use of Proton Pump Inhibitors","volume":"22","author":"Shin YH","year":"2019","unstructured":"Shin YH, Gong HS, Baek GH. Lower Trabecular Bone Score is Associated With the Use of Proton Pump Inhibitors. J Clin Densitom. 2019, 22:236-42. 10.1016\/j.jocd.2018.06.008","journal-title":"J Clin Densitom"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13743","article-title":"Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score","volume":"89","author":"Vinolas H","year":"2018","unstructured":"Vinolas H, Grouthier V, Mehsen-Cetre N, et al.. Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score. Clin Endocrinol (Oxf). 2018, 89:148-54. 10.1111\/cen.13743","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad724","article-title":"Trabecular bone score as a marker of skeletal fragility across the spectrum of chronic kidney disease: a systematic review and meta-analysis","volume":"109","author":"Bioletto F","year":"2024","unstructured":"Bioletto F, Barale M, Maiorino F, et al.. Trabecular bone score as a marker of skeletal fragility across the spectrum of chronic kidney disease: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024, 109:e1534-43. 10.1210\/clinem\/dgad724","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins JP","year":"2024","unstructured":"Higgins JP, Morgan RL, Rooney AA, et al.. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024, 186:108602. 10.1016\/j.envint.2024.108602","journal-title":"Environ Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-008-9170-1","article-title":"Acid-suppressive medications and risk of bone loss and fracture in older adults","volume":"83","author":"Yu EW","year":"2008","unstructured":"Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008, 83:251-9. 10.1007\/s00223-008-9170-1","journal-title":"Calcif Tissue Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative","volume":"170","author":"Gray SL","year":"2010","unstructured":"Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010, 170:765-71. 10.1001\/archinternmed.2010.94","journal-title":"Arch Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.200","article-title":"The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos)","volume":"107","author":"Targownik LE","year":"2012","unstructured":"Targownik LE, Leslie WD, Davison KS, et al.. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012, 107:1361-9. 10.1038\/ajg.2012.200","journal-title":"Am J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2709-0","article-title":"Bone density in proton pump inhibitors users: a prospective study","volume":"33","author":"Ozdil K","year":"2013","unstructured":"Ozdil K, Kahraman R, Sahin A, et al.. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int. 2013, 33:2255-60. 10.1007\/s00296-013-2709-0","journal-title":"Rheumatol Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2344","article-title":"Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study","volume":"30","author":"Solomon DH","year":"2015","unstructured":"Solomon DH, Diem SJ, Ruppert K, et al.. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res. 2015, 30:232-9. 10.1002\/jbmr.2344","journal-title":"J Bone Miner Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-015-0699-6","article-title":"Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors","volume":"34","author":"Bahtiri E","year":"2016","unstructured":"Bahtiri E, Islami H, Hoxha R, et al.. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab. 2016, 34:571-9. 10.1007\/s00774-015-0699-6","journal-title":"J Bone Miner Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.481","article-title":"Long-term proton pump inhibitor use is not associated with changes in bone strength and structure","volume":"112","author":"Targownik LE","year":"2017","unstructured":"Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017, 112:95-101. 10.1038\/ajg.2016.481","journal-title":"Am J Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4754","article-title":"PPI-induced changes in plasma metabolite levels influence total hip bone mineral density in a UK cohort","volume":"38","author":"Zhang X","year":"2023","unstructured":"Zhang X, Adebayo AS, Wang D, et al.. PPI-induced changes in plasma metabolite levels influence total hip bone mineral density in a UK cohort. J Bone Miner Res. 2023, 38:326-34. 10.1002\/jbmr.4754","journal-title":"J Bone Miner Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae598","article-title":"Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality","volume":"110","author":"Bioletto F","year":"2025","unstructured":"Bioletto F, Pusterla A, Fraire F, et al.. Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality. J Clin Endocrinol Metab. 2025, 110:e2071-9. 10.1210\/clinem\/dgae598","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12866","article-title":"Proton pump inhibitors use and change in bone mineral density","volume":"19","author":"Arj A","year":"2016","unstructured":"Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016, 19:864-8. 10.1111\/1756-185X.12866","journal-title":"Int J Rheum Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1259\/dmfr.20200505","article-title":"Proton pump inhibitors and mandibular bone quality: A preliminary study","volume":"50","author":"Co\u015fgunarslan A","year":"2021","unstructured":"Co\u015fgunarslan A, Canger EM, Soydan \u00c7abuk D. Proton pump inhibitors and mandibular bone quality: A preliminary study. Dentomaxillofac Radiol. 2021, 50:20200505. 10.1259\/dmfr.20200505","journal-title":"Dentomaxillofac Radiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_550_25","article-title":"Over-the-counter drug development in developing countries","volume":"57","author":"Bharati V","year":"2025","unstructured":"Bharati V, Rajaram S, Prakash A, Medhi B. Over-the-counter drug development in developing countries. Indian J Pharmacol. 2025, 57:207-11. 10.4103\/ijp.ijp_550_25","journal-title":"Indian J Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2018.25.3.141","article-title":"Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis","volume":"25","author":"Nassar Y","year":"2018","unstructured":"Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J Bone Metab. 2018, 25:141-51. 10.11005\/jbm.2018.25.3.141","journal-title":"J Bone Metab"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116668","article-title":"Bone microstructure in proton pump inhibitor users","volume":"168","author":"Kondapalli A","year":"2023","unstructured":"Kondapalli A, Agarwal S, Germosen C, Bucovsky M, Colon I, Kil N, Walker M. Bone microstructure in proton pump inhibitor users. Bone. 2023, 168:116668. 10.1016\/j.bone.2022.116668","journal-title":"Bone"},{"key":"ref41","unstructured":"FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. (2025). (20251016). Accessed: April 7, 2026: http:\/\/web.archive.org\/web\/20251214091124\/https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-p...."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1159\/000528199","article-title":"Trabecular bone score as an index of bone fragility in patients with acromegaly: a systematic review and meta-analysis","volume":"113","author":"Bioletto F","year":"2023","unstructured":"Bioletto F, Barale M, Prencipe N, et al.. Trabecular bone score as an index of bone fragility in patients with acromegaly: a systematic review and meta-analysis. Neuroendocrinology. 2023, 113:395-405. 10.1159\/000528199","journal-title":"Neuroendocrinology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49872","article-title":"Use of proton pump inhibitors and risk of fracture in adults: a review of literature","volume":"15","author":"Paudel Y","year":"2023","unstructured":"Paudel Y, Najam B, Desai HN, et al.. Use of proton pump inhibitors and risk of fracture in adults: a review of literature. Cureus. 2023, 15:e49872. 10.7759\/cureus.49872","journal-title":"Cureus"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116868","article-title":"Evidence that pyrophosphate acts as an extracellular signalling molecule to exert direct functional effects in primary cultures of osteoblasts and osteoclasts","volume":"176","author":"Bourne LE","year":"2023","unstructured":"Bourne LE, Davies BK, Millan JL, et al.. Evidence that pyrophosphate acts as an extracellular signalling molecule to exert direct functional effects in primary cultures of osteoblasts and osteoclasts. Bone. 2023, 176:116868. 10.1016\/j.bone.2023.116868","journal-title":"Bone"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.28982\/josam.7690","article-title":"Bone mineral changes in young adult females on short-term proton pump inhibitor: A retrospective cohort study","volume":"8","author":"Kucukdemirci O","year":"2024","unstructured":"Kucukdemirci O, Kapucu K, Mavis O. Bone mineral changes in young adult females on short-term proton pump inhibitor: A retrospective cohort study. J Surg Med. 2024, 8:85-9. 10.28982\/josam.7690","journal-title":"J Surg Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S223118","article-title":"The association between prolonged proton pump inhibitors use and bone mineral density","volume":"12","author":"Fattahi MR","year":"2019","unstructured":"Fattahi MR, Niknam R, Shams M, Anushiravani A, Taghavi SA, Omrani GR, Mahmoudi L. The association between prolonged proton pump inhibitors use and bone mineral density. Risk Manag Healthc Policy. 2019, 12:349-55. 10.2147\/RMHP.S223118","journal-title":"Risk Manag Healthc Policy"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00473","article-title":"Proton pump inhibitors and osteoporosis: is collagen a direct target?","volume":"11","author":"Ghebre YT","year":"2020","unstructured":"Ghebre YT. Proton pump inhibitors and osteoporosis: is collagen a direct target?. Front Endocrinol (Lausanne). 2020, 11:473. 10.3389\/fendo.2020.00473","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies","volume":"37","author":"Cheungpasitporn W","year":"2015","unstructured":"Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al.. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015, 37:1237-41. 10.3109\/0886022X.2015.1057800","journal-title":"Ren Fail"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-022-00448-x","article-title":"Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways","volume":"28","author":"Cheng Z","year":"2022","unstructured":"Cheng Z, Liu Y, Ma M, et al.. Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways. Mol Med. 2022, 28:21. 10.1186\/s10020-022-00448-x","journal-title":"Mol Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00882-9","article-title":"Proton pump inhibitors inhibit PHOSPHO1 activity and matrix mineralisation in vitro","volume":"109","author":"Staines KA","year":"2021","unstructured":"Staines KA, Myers K, Little K, Ralston SH, Farquharson C. Proton pump inhibitors inhibit PHOSPHO1 activity and matrix mineralisation in vitro. Calcif Tissue Int. 2021, 109:696-705. 10.1007\/s00223-021-00882-9","journal-title":"Calcif Tissue Int"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff MS","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022, 33:2049-102. 10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478129-impact-of-proton-pump-inhibitor-therapy-on-bone-mineral-density-an-updated-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:05:21Z","timestamp":1775725521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478129-impact-of-proton-pump-inhibitor-therapy-on-bone-mineral-density-an-updated-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.106698","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}